Market Snapshot
On Tuesday, 20 October 2026, the shares of Saniona AB (SANION.ST) closed down 0.89 % in a 24‑hour trading window that ended at 23:44 Central Europe time. The latest closing price stood at approximately SEK 10.56. With a market capitalization of SEK 1.4 billion and an outstanding supply of 138.5 million shares, the company’s trading volume for the past day was around SEK 3 million. Over the month‑to‑month interval, the stock has risen 4.92 %. The 200‑day simple moving average currently sits at SEK 15.20, while the 52‑week high and low are SEK 28.30 (recorded on 29 January 2026) and SEK 8.52 (recorded on 7 October 2026), respectively.
Clinical Development Milestone
Saniona’s most recent corporate action is the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its lead candidate SAN2465, a novel therapeutic intended to treat severe depression. The company plans to initiate a phase 1 study before year‑end, contingent upon regulatory clearance. According to Saniona’s chief medical officer, SAN2465 aims to provide rapid‑onset antidepressant effects comparable to ketamine but with a reduced side‑effect profile, addressing a critical unmet need in psychiatric medicine. This IND filing marks a pivotal transition from preclinical research to human trials, potentially accelerating the timeline toward commercial availability.
Peer Performance Overview
| Ticker | 24‑h Change | Current Price (SEK) | Market Cap (SEK bn) | P/E Ratio |
|---|---|---|---|---|
| Siljansvik (DE.ST) | –6.2 % | 113.6 | 1.6 | 15.75 |
| Paxman (PAX.ST) | +3.16 % | 65.9 | 1.5 | – |
| Inission (INISS‑B.ST) | –1.37 % | 69.6 | 1.6 | 21.3 |
| Byggpartner N (BYGGP.ST) | –0.83 % | 36.0 | 1.6 | 10.13 |
Inission AB has announced a memorandum of understanding with Ukrainian defence contractor DevDroid, focusing on the development and production of electronics and remote‑control systems for unmanned ground vehicles. This partnership is expected to enhance Inission’s industrial electronics capabilities and strengthen its foothold in the defence sector.
Company Profile
Saniona AB is a Denmark‑based biopharmaceutical firm headquartered in Ballerup, Sweden. The company focuses on discovery, development, and delivery of innovative treatments for rare diseases. Its clinical‑stage pipeline targets conditions such as hypothalamic obesity, Prader‑Willi syndrome, and rare neuropathic disorders, and is supported by a proprietary ion‑channel drug discovery platform. For further details, visit www.saniona.com .
